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Abstract Non-steroidal anti-inﬂammatory drugs (NSA-
IDs) that act as cyclo-oxygenase (COX) inhibitors are
commonly used in the treatment of a range of headache
disorders, although their mechanism of action is unclear.
Indomethacin is of particular interest given its very special
effect in some primary headaches. Here the in vivo tech-
nique of intravital microscopy in rats has been utilised as a
model of trigeminovascular nociception to study the
potential mechanism of action of indomethacin. Dural
vascular changes were produced using electrical (neuro-
genic) dural vasodilation (NDV), calcitonin gene-related
peptide (CGRP) induced dural vasodilation and nitric oxide
(NO) induced dural vasodilation using NO donors. In each
of these settings the effect of intravenously administered
indomethacin (5 mg kg
-1), naproxen (30 mg kg
-1) and
ibuprofen (30 mg kg
-1) was tested. All of the tested drugs
signiﬁcantly inhibited NDV (between 30 and 52%). Whilst
none of them was able to inhibit CGRP-induced dural
vasodilation, only indomethacin reduced NO induced dural
vasodilation (35 ± 7%, 10 min post administration). We
conclude NSAIDs inhibit release of CGRP after NDV
without an effect on CGRP directly. Further we describe a
differentiating effect of indomethacin inhibiting nitric
oxide induced dural vasodilation that is potentially relevant
to understanding its unique action in disorders such as
paroxysmal hemicrania and hemicrania continua.
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Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
probably among the most widely used analgesics used to
treat headache, including many of the primary headache
disorders. For migraine, where they are the ﬁrst line
treatment for acute attacks, they offer the most cost
effective treatment showing only minor side effects [1].
Although these substances have been used clinically for
many years, and it is known that they share mechanisms
that involve inhibition of the different cyclooxygenases
(COX) [2, 3], it is not clear which mechanisms, apart from
the known COX-1/-2 inhibition, deﬁnes their different
clinical proﬁles relevant for the treatment of headaches.
The role of some NSAIDs has been investigated previously
in animal models of migraine pathways and have demon-
strated an inhibitory effect on neuronal ﬁring in the TCC
after dural stimulation [4, 5] and naproxen has been shown
capable of inhibiting central sensitization [6], a phenome-
non often thought to contribute, at the very least, to the
cutaneous allodynia observed in migraine patients. Among
the NSAIDs indomethacin stands out for its particular
effect on a range of primary headache disorders that are
regarded as indomethacin-sensitive, notably paroxysmal
hemicrania and hemicrania continua [7], although the basis
for is special effect is unknown.
Indomethacin has been shown to be effective in the
model of trigeminovascular nociception using intravital
microscopy of the dural vasculature [8]. Also, by testing
the effect of various intracisternally administered COX
inhibitors, including indomethacin, on trigeminal ganglion
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[9], highlighting the likelihood of COX being a potential
target within the CNS for the treatment of headache. Like
other NSAIDs indomethacin inhibits COX-1/-2 and in this
aspect differs from others in the ratio of that effect [10–12].
However, these differences in COX effects are not so
marked, such that additional mechanisms have been dis-
cussed and the exact mechanism of action relevant to
indomethacin-sensitive headaches remains unclear.
Intravital microscopy as a model for trigeminovascular
nociception monitors dural vessel diameter in response to
external stimuli, chemical or electrical, and relates the
dilatory response to trigeminovascular activation. Utilizing
this well established technique [13, 14] it has been shown
that indomethacin causes vasoconstriction of nitric oxide-
induced vasodilation [8]. However, no direct comparison
with other NSAIDs has been made within the same
experimental setup that uses dural vessels as a model of
trigeminovascular activation. Here we aimed to measure
and compare effects of indomethacin, naproxen and ibu-
profen on vasodilation of the middle meningeal artery,
induced by electrical stimulation of the dura mater, as well
as chemical stimulation by intra arterial application of the
known vasodilators CGRP and sodium nitroprusside, a
nitric oxide donor. Both CGRP [15] and NO donors [16]
have been demonstrated to cause vasodilation of intracra-
nial blood vessels and an immediate headache in all
patients, but also cause a delayed migraine in migraineurs.
They therefore provide important translational approaches
for understanding the mechanism of action of therapeutics.
Separating unique mechanisms of action of indomethacin
is crucial in developing new treatments independent from
COX-1/-2 inhibition, which may have less gastrointestinal
side effects yet still beneﬁt patients with ‘‘indomethacin-
sensitive’’ headaches.
Methods
General procedures
All experiments were conducted under license of the
University of California, San Francisco Institutional Ani-
mal Care and Use Committee and conforming to the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
For experiments male Sprague–Dawley rats (280–390 g)
were anesthetized with sodium pentobarbital (60 mg kg
-1;
i.p.). The left femoral artery and veins of both sides were
cannulated for blood pressure monitoring (CT-1000? ALM
932, CWE Inc., Ardmore, PA, USA) and further administra-
tion of anesthetics (pentobarbital 25–30 mg kg
-1 h
-1)a n d
drug administration, respectively. The animals were
ventilated with oxygen enriched air, 2–3 ml, 80–100 stro-
kes min
-1 (Small rodent ventilator––Model 683, Harvard
Instruments, Kent, U.K.) after cannulation with a tracheal
tube. End Tidal CO2 was monitored (Capstar––100, CWE
Inc., Ardmore, PA, USA) and kept between 3.5 and 4.5%. A
thermostatically controlled homeothermic blanket system
wasusedtokeepthebodytemperatureinphysiologicalrange.
Thebloodpressure(BP),endtidalCO2,andtemperaturewere
electronically displayed. Animals were ﬁxed in a stereotactic
frame for the surgery and recordings. The withdrawal reﬂex
after paw pinch and testing of the corneal reﬂexes were
recorded allowing monitoring of the depth of anesthesia.
Data for all experiments were displayed and saved on a
personal computer using an online data analysis system
(Power 1401plus, CED and Spike5 software, UK).
At the end of the experiments animals were euthanized
by a lethal dose of pentobarbital.
Intravital microscopy
The carotid artery was cannulated for all experiments and
used to administer the chemical dilators, CGRP and the NO
donorsodiumnitroprusside(SNP).Ithasbeen demonstrated
previouslythat usingthe intracarotid route ofadministration
reduces signiﬁcantly the overall concentration of molecules
required to induce maximal dural blood vessel dilation,
while minimizing cardiovascular effects compared to the
more commonly used intravenous route [14].
After exposing the skull, the parietal bone of the right or
left side was thinned using a saline cooled dental drill until
the underlying vessels of the dura mater were clearly visible
and the skull was left intact (closed window). The area was
then covered with mineral oil (37C) and a branch of the
middle meningeal artery (MMA) was then focused on and
projected onto a TV monitor using an intravital microscope
(Microvision MV2100, UK). On-line monitoring of the
blood vessel diameter was achieved through a video
dimension analyzer (Living System Instrumentation, USA)
[17]. After a resting period and evaluation of a steady vessel
diameter, one of the following protocols was applied.
Neurogenic dural vasodilation (NDV)
A bipolar stimulation electrode (NE 200, Clark Electro-
medical) was placed within a range of about 200 lm to the
monitored vessel. The bone adjacent to the MMA was
stimulated with constant settings for stimulation adjusted to
5 Hz 1 ms for 10 s (Grass Stimulator S88, Grass Instru-
mentation,USA).Foreachanimalthevoltagewasincreased
until a maximal dilation was observed, the resulting current
was monitored on an oscilloscope ranging between 100 and
160 lA. All following stimulations were then performed
using this voltage [18, 19].
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123Calcitonin gene-related peptide (CGRP)-induced dilation
CGRP (1 lgk g
-1 dissolved in 0.9% NaCl) was given i.a.
over 3 min and demonstrated the maximal dilatory effect.
Following a recovery period of 17 min, the infusion of
CGRP was then repeated. By following this time pattern
it was possible to ensure a sufﬁcient recovery as well as
to evaluate vasodilatory responses at the same time
points as with nitric oxide induced dilation. The two
vascular responses were recorded and summarized as the
baseline response. After recovery from the second infu-
sion of CGRP the control or one of the COX inhibitors
was injected i.v. The pattern of CGRP-injection followed
by a 17 min recovery period was then repeated for four
times starting 10 min after the injection of the vehicle or
drug.
Nitric oxide induced dilation
SNP (2 lgk g
-1 min
-1 dissolved in 0.9% NaCl) was given
i.a. over 5 min as similar doses have shown a maximal
dilatory effect [8]. This was followed by a recovery period
of 15 min, the injection of SNP was then repeated. The two
vascular responses were recorded and summarized as the
baseline response. 15 min after the second baseline either
control or one of the drugs was injected i.v. The injection
of the NO donor SNP followed by a 15 min recovery
period was repeated 10 min after the injection of the drug
for four times. Each animal only received a single dose of a
NSAID.
Drugs
For intravenous application indomethacin was dissolved in
0.9% NaCl solution (5 mg ml
-1) and administered at the
dose of 5 mg kg
-1. Naproxen and Ibuprofen were dis-
solved in 0.9% NaCl (30 mg ml
-1) and the dose for
administration was 30 mg kg
-1. An equal volume of saline
was used in the control group. All solutions were pH
adjusted to pH 8–8.3.
Statistics
Statistical analysis was carried out using SPSS (18.0, IL,
USA). For repeated measures an analysis of variance
(ANOVA) was performed. In case the assumption of
sphericity was violated Greenhouse–Geisser corrections
were applied. Bonferroni correction was applied for mul-
tiple comparisons if applicable. Statistical signiﬁcance was
set at P\0.05. In case of P values\0.05 post-hoc com-
parisons were made using independent t tests for group
comparisons of the different interventions. All results are
expressed as percentages of baseline responses.
Results
General
A total of 63 animals were used for these experiments. The
monitored vessel diameters at rest ranged between 40 and
150 lm. The slow intravenous administration of indo-
methacin, naproxen and ibuprofen caused a slight and
transient blood pressure increase accompanied by a light
constriction of the monitored vessel. However vessel
diameter recovered back to baseline readings before any
induced dilation similar to previous reports for indometh-
acin [8].
Vehicle control had no effect on the baseline values of
BP or vessel diameter.
Neurogenic dural vasodilation (NDV)
NDV was used to examine the effect of all test substances
in 23 animals. Stimulation dilated the dural vessels by
239 ± 14% of their resting diameter. Whilst the baseline
responses of the control and drug groups were stable and
administration of vehicle control (N = 5) did not alter the
vascular responses (F4,16 = 0.562, P[0.05), all tested
drugs attenuated NDV.
Indomethacin (N = 6) signiﬁcantly inhibited NDV
(F4,20 = 3.043, P\0.05) by 29 ± 5% at 10 min (t9 =
5.349, P\0.001), by 20 ± 8% at 25 min (t9 = 2.683,
P\0.05) and by 30 ± 12% at 40 min (t9 = 2.586,
P\0.05) when compared to control. Naproxen (N = 6)
inhibited NDV (F4,20 = 6.978, P B 0.001) by 44 ± 10%
at 10 min (t9 = 4.383, P\0.05), by 34 ± 12% at 25 min
(t9 = 2.776, P\0.05), by 52 ± 13% at 40 min (t9 =
3.993, P\0.05) and by 35 ± 14% at 55 min (t9 = 2.550,
P\0.05) when compared to control. Ibuprofen (N = 6)
signiﬁcantly attenuated NDV (F4,20 = 6.654, P B 0.001)
by 26 ± 10% at 25 min (t9 = 2.562, P\0.05), by
30 ± 12% at 40 min (t9 = 2.440, P\0.05) and by
28 ± 9% at 55 min (t9 = 3.007, P\0.05) when com-
pared to control (Fig. 1).
Calcitonin gene-related peptide induced dilation
A total of 20 animals were used for monitoring the effects
of the tested drugs on CGRP induced dilation. Infusion of
CGRP induced an increase of the vessel diameter to
191 ± 5% of the resting state. CGRP infusion also caused
a transient drop of blood pressure within physiological
range, not exceeding 3 min post infusion. Intravenous
administration of vehicle control (N = 5), indomethacin
(N = 5), naproxen (N = 5) and ibuprofen (N = 5) had no
effect on the NO-induced vessel dilation (P C 0.21)
(Fig. 2). The blood pressure was reduced to 78 ± 2% of
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short lasting with an immediate recovery to baseline
reading within 3–5 min. The administration of vehicle
control or any of the drugs used did not alter this response.
Nitric oxide induced dilation
The effect of the selected compounds was tested on NO
induced dilation in 20 animals by intra-arterial
administration of SNP. Infusion of SNP induced an
increase of the vessel diameter to 185 ± 7% of the resting
state, accompanied by a minor and transient drop in blood
pressure, which recovered to baseline readings within
3 min of the end of the infusion. Administration of control
(N = 5), naproxen (N = 5) and ibuprofen (N = 5) had no
effect on the NO-induced vessel dilation (P C 0.17).
However, indomethacin (N = 5) did inhibit the vasodila-
tion (F4,16 = 5.143, P\0.05) at 10 min by 35 ± 7%
(t8 = 4.773, P B 0.001), 30 min by 33 ± 12% (t8 =
2.729, P\0.05) 50 min by 31 ± 13% (t8 = 2.425,
P\0.05) and 70 min by 34 ± 14% (t8 = 2.324,
P\0.05) when compared to control (Fig. 3a). Infusion of
the SNP induced a decrease of the blood pressure to
71 ± 2% of readings at rest. The BP decrease was short
lasting with a full recovery to baseline readings within
3–5 min. Whilst vehicle control, naproxen and ibuprofen
left the BP response unaltered (P C 0.13), indomethacin
decreased the percentage of BP reduction induced by SNP
infusion (F4,16 = 3.218, P\0.05). When compared to
control indomethacin reduced the BP response to SNP
infusion by 23 ± 10% (t8 = 2.729, P\0.05) 10 min after
administration, 30 ± 8% (t8 = 2.342, P\0.05) 30 min
after administration, 31 ± 3% (t8 = 9.757, P\0.001)
50 min after administration and 37 ± 13% (t8 = 2.942,
P\0.05; Fig. 3b).
Discussion
The data demonstrate indomethacin, naproxen and ibu-
profen are able to inhibit dural vasodilation induced by
electrical stimulation, with ibuprofen showing a later onset
of the inhibition, and indomethacin a shorter duration of
the effect when compared to the two other drugs used.
There was no inhibition of CGRP infusion induced dural
vasodilation with any of the tested drugs. The most inter-
esting ﬁnding is that indomethacin was able to inhibit NO
induced vasodilation as well reducing the hypotensive
effect of the SNP infusion, whereas naproxen and ibupro-
fen had no effect. This clearly separates indomethacin from
the other NSAIDs tested and suggests that indomethacin
can inhibit mechanisms related NO. Understanding the NO
inhibiting effect of indomethacin in concert with the
COX1/2 effects may hold an important key for the devel-
opment of new approaches to the management of indo-
methacin-sensitive headaches.
Drug doses in our study were based on the LD10 of
indomethacin after oral dosage of indomethacin in rat
being slightly higher than the dose used [20]. The doses of
naproxen and ibuprofen were adjusted according to the
clinically recommended maximum daily dose for headache
treatment in humans, e.g. 200 mg day
-1 indomethacin,
Fig. 1 Effect of COX inhibitors on electrical stimulation induced
vasodilation of the middle meningeal artery in intravital microscopy.
After the baseline response was established one of the drugs
(indomethacin 5 mg kg
-1, naproxen 30 mg kg
-1 or ibuprofen 30
mg kg
-1)wasappliedintravenously,followedbyfourfurtherelectrical
stimulations with a 15 min recovery period, starting 10 min after the
administration of one of the drugs. Each of the administered drugs was
able to signiﬁcantly attenuate neurogenic vasodilation. *P\0.05
Fig. 2 Effect of COX inhibitors on repeated CGRP
(0.33 lgk g
-1min
-1 over 3 min intra-arterial) induced vasodilations
in intravital microscopy. After the baseline response was established
one of the drugs (indomethacin 5 mg kg
-1, naproxen 30 mg kg
-1 or
ibuprofen 30 mg kg
-1) was applied intravenously, followed by four
further CGRP infusions with a 17 min recovery period, starting
10 min after the administration of one of the drugs. None of the drugs
altered the vessel response to CGRP infusion
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-1 naproxen or 1200 mg day
-1 ibuprofen
(ratio: 1:6:6). As all of these drugs are about 98% absorbed
in humans, we used the doses that reﬂect the ratio used in
clinical practice. However, the inhibition of dural vasodi-
lation shown for indomethacin reﬂects somewhat previous
results [8] with effect sizes between the ones demonstrated
for the doses of 3 and 10 mg kg
-1 used in the reported
experiments, with similar doses having been used suc-
cessfully in previous work [21, 22].
Neurogenic vasodilation is believed to act via neuronal
release of CGRP from trigeminovascular neurons, meaning
that the effect seen with this technique must be due to an
interaction of the successfully used drugs with either the
release of CGRP from the trigeminovascular neurons, the
drug with the CGRP or the CGRP receptor itself, or with
both [18, 23]. CGRP acts as a vasodilator via an induction
of adenylate cyclase within the vascular smooth muscle
cells [24]. The observation that none of the tested drugs
inhibited CGRP induced vasodilation suggests the effect of
these drugs is most likely via pre-synaptic inhibition of
CGRP release from trigeminovascular neurons.
NO induced vasodilation can occur via an activation of
guanylate cyclase, which in turn raises the cyclic guanosine
monophosphate (cGMP) synthesis. Relaxation of the
smooth muscle cell and thereby vasodilation is ﬁnally
caused by the decrease of Ca
2? [25]. However, additional
mechanisms that include a coupling of NO and CGRP
release have been discussed [8, 18, 26, 27]. Great interest
lies on the involvement of NO induced mechanisms within
the trigeminal pathway since it is known that NO can
induce headache with the clinical phenotype of migraine
[28, 29]. This migraine-like headache is delayed and
develops after a more immediate onset headache with
glyceryltrinitrate (GTN) administration. Not limited to
migraine, it also is known that GTN can trigger attacks in
cluster headache patients during an active headache epi-
sode [30] and it has been reported that GTN can trigger
paroxysmal hemicrania [31]. Migraine after GTN develops
several hours after administration, while cluster headache
takes tens of minutes, suggesting direct vasodilation is the
cause of the pain. Indeed vasodilation is not present in
migraine when the attack starts [32]. The suggested
mechanisms for the development of these headaches are
therefore believed to be transmitted by second messengers.
In turn the case report of the GTN induced paroxysmal
headache demonstrates an early onset. The observation that
indomethacin was able to inhibit NO induced vasodilation
might therefore be important in understanding its effect in
paroxysmal hemicrania or hemicrania continua, indeed
acting as a marker for the effect. Unfortunately our
understanding of the underlying mechanisms of NO-
induced headache is still very limited.
Indomethacin does inhibit NO production from rat
microglia [33]. Indeed NO generation is involved in the
cranial parasympathic loop [34] that is active in trigeminal
autonomic cephalalgias (TACs) [35]. In a study monitoring
the meningeal blood ﬂow during local application of
vasodilators as well as potential antagonists it was con-
cluded that NO dependent blood ﬂow release is indepen-
dent of the release of prostaglandins, a product of
cyclooxygenases, but is co-induced by a NO triggered
CGRP release [27]. The model used did not reﬂect tri-
geminal activation itself, and only local effects were
monitored. It is not known if the mechanism accompanying
the vasodilatory effect is the cause of the induced
Fig. 3 Effect of COX inhibitors on dural vasodilation, induced by
repeated sodium nitroprusside infusions, 2 lgk g
-1 min
-1 over 5 min
intra arterial, in intravital microscopy (a) and on the blood pressure
decrease caused by the repeated infusion of sodium nitroprusside
prior and post drug or control administration (b). After the baseline
response was established one of the drugs (indomethacin 5 mg kg
-1,
naproxen 30 mg kg
-1 or ibuprofen 30 mg kg
-1) was applied intra-
venously, followed by four further sodium nitroprusside infusions
with a 15 min recovery period, starting 10 min after the administra-
tion of one of the drugs. Of all drugs used only indomethacin shows
an inhibitory effect on nitric oxide induced vasodilation as well as on
the blood pressure decrease induced by the infusion of sodium
nitroprusside. *P\0.05
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123paroxysmal hemicrania, as NO is highly capable of cross-
ing the blood brain barrier and local effects within certain
areas of the CNS are highly probable. It is very important
to note that the vasodilatory effect of NO itself is not likely
to be the pain inducing mechanism, it is in fact more likely
that other mechanisms induced by NO, that are accompa-
nied by the vasodilatory effect, are causing the early onset
headache.
Painful stimuli within the trigeminovascular system can,
themselves, cause vasodilation, while pain is not neces-
sarily caused by vasodilation [35]. It has been documented
in in vitro experiments that elevated NO levels are capable
of increasing COX-1 activity within trigeminal satellite
cells [36], demonstrating a non-vascular mechanism of NO
within the migraine pathway. In earlier experiments it was
also shown that COX-2 inhibition but not COX-1 inhibition
can decrease the level of neuronal nitric oxide synthase
induction as induced by NO donors [37]. The substances
used in our experiment all show activity on COX-1 and -2
with different pharmacologically kinetics. Indomethacin
shows time dependent tight binding, naproxen shows time
dependent weak binding and ibuprofen acts via competitive
inhibition on COX-1/-2 [10].
Indomethacin, as well as other NSAIDs, shows a good
penetrability of the blood brain barrier and therefore can
target mechanisms within the CNS [38, 39]. Naproxen
showed the lowest concentrations within the brain in
comparison to the plasma levels but did reach effective
doses [38]. In the study of Parepally et al. [39] only ibu-
profen had a saturable transport, which may explain its
delayed effect on NDV compared to indomethacin and
naproxen. A mechanism where no direct correlation to the
COX inhibitory effect of the NSAIDs can be seen was
uncovered after the observation has been made that long
term medication with NSAIDs can lower the risk for
development Alzheimer’s disease [40]. Eriksen et al. [38]
were able to show that indomethacin and ibuprofen were
able to decrease signiﬁcantly formation of the amyloid b 42
amino acid form of amyloid beta, whilst naproxen had no
signiﬁcant effect. Taken together it is plausible that the site
of action of indomethacin in headache may be within the
central nervous system.
In conclusion, each of the NSAIDs tested, indomethacin,
ibuprofen and naproxen, have clear effects on neurogenic
dural vasodilation (NDV) in line with their efﬁcacy in
migraine. Moreover, there was no effect of these com-
pounds on CGRP-induced vasodilation suggesting that the
NDV effect is prejunctional. Only indomethacin inhibits
NO-induced dural vasodilation. It is plausible that the NO
effect is the crucial added mechanism that allows indo-
methacin to be so effective in conditions such as parox-
ysmal hemicrania and hemicrania continua. These offer the
prospect of developing medicines targeting NO
mechanisms that may then provide novel approaches to the
treatment of indomethacin-sensitive headaches.
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